Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

100.09
+1.231.24%
Post-market: 100.090.00000.00%19:43 EDT
Volume:342.44K
Turnover:34.21M
Market Cap:1.54B
PE:9.32
High:100.35
Open:98.35
Low:98.35
Close:98.86
52wk High:108.66
52wk Low:72.94
Shares:15.40M
Float Shares:15.40M
Volume Ratio:0.75
T/O Rate:2.22%
Dividend:1.43
Dividend Rate:1.43%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

Perspective Therapeutics [212Pb]VMT01 Melanoma Trial Data Set for SITC 2026 Presentation

Reuters
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Oct 02

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Oct 02

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Oct 02

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS
·
Oct 02

J&J - 60% Scalp Psoriasis, 89% Genital Psoriasis Patients Achieve Complete Clearance at Week 112

THOMSON REUTERS
·
Oct 02

J&J - Safety Findings Through Week 112 Consistent with Icotyde Profile, no New Safety Signals

THOMSON REUTERS
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Oct 02

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 02

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02